<DOC>
	<DOCNO>NCT01401478</DOCNO>
	<brief_summary>Eighty-six eligible participant secondary hyperparathyroidism enrol thirteen site Russia . Planned therapy six month . Participants Stage 5 Chronic Kidney Disease hyperparathyroidism hemodialysis include study . Ability Zemplar , ( paricalcitol ) low intact Parathyroid Hormone level assess study .</brief_summary>
	<brief_title>Observational Program Zemplar Patients With End Stage Chronic Kidney Disease Parathyroid Disorder Hemodialysis Russian Federation</brief_title>
	<detailed_description>Eighty-six eligible participant secondary hyperparathyroidism enrol thirteen site Russia . Study drug administer per local prescribing guideline . Planned therapy six month . Intact Parathyroid Hormone measure Screening visit . All participant meet inclusion criterion fail meet exclusion criterion include study . Adverse event monitor throughout observation period ( 30 day last dose Zemplar ) . Ability Zemplar low intact Parathyroid Hormone level assess throughout study . Proportion participant level intact Parathyroid Hormone 150 - 300 pg/mL state primary endpoint . Calcium Phosphorus elevation also measure throughout study . The selected population representative relation take Zemplar routine practice . Participants contraindication Zemplar therapy ( per local label ) include study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>1 . Age 1865 year 2 . Chronic Kidney Disease stage 5 receive hemodialysis 3 . Authorization ( Consent ) Use/Disclosure Data sign patient 4 . Planned prescription Zemplar treatment due fair clinical need irrespectively participation current program accord local label within 2 week screen program 5 . Screening intact Parathyroid Hormone level ( measure earlier 1 month first dose Zemplar ) 300 900 pg/mL 1 . Contraindications Zemplar indicate approved label , include limited hypersensitivity , hypervitaminosis D ( serum D3 level 32 ng/mL ) , concomitant use vitamin D phosphates , lactation period , pregnancy 2 . Any experimental drug within period 30 day inclusion program 3 . Screening Ca x P &gt; 65 mg˄2/dL˄2 4 . Screening normalized serum total calcium &gt; 10.2 mg/dL 5 . Necessity calcitonin maintenance oral intravenous glucocorticoid , drug could affect calcium bone metabolism , females stable estrogen and/or progestin therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Chronic Renal Insufficiency</keyword>
</DOC>